{
  "docId": "019de077-8566-7247-8a65-bb40d287c138",
  "docSlug": "3a5ef691e659aba2296672e3bbfa035c",
  "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 36 slides",
  "authorId": "an2-therapeutics",
  "authorName": "AN2 Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2025-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 36,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "Uses a timeline-based framework to categorize clinical milestones and market opportunities.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-8566-7247-8a65-bb40d287c138/6",
  "deckHref": "/decks/019de077-8566-7247-8a65-bb40d287c138",
  "deckJsonHref": "/decks/019de077-8566-7247-8a65-bb40d287c138.json",
  "deckAnchorHref": "/decks/019de077-8566-7247-8a65-bb40d287c138#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.95,
        "x": 0.03,
        "y": 0.81
      },
      "kind": "callout",
      "text": "Cash runway through 2027",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4aa96543-725f-4d62-a454-40b5b53550e5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.31,
        "x": 0.67,
        "y": 0.25
      },
      "kind": "list",
      "text": "Long-Term: Oncology and ID platform expansion.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "197c87d4-6076-41a5-a26d-c92583fdb186",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.31,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "list",
      "text": "Near-Term: NTM Lung Disease and Melioidosis programs with $1B+ opportunity.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "40e9b750-8761-4257-a974-71f03e09cd66",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.31,
        "x": 0.35,
        "y": 0.25
      },
      "kind": "list",
      "text": "Mid-Term: Chagas Disease program with $500M-$1B opportunity.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "de4fac94-7dfd-4dec-8959-f46caa8c8fa9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.22,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "PRV= Priority review voucher; HMIC= High market impact customers; TEAE's= Treatment emergent adverse events",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "17e26ea8-201d-46cb-9da4-1f061b7a07c1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.68,
        "x": 0.16,
        "y": 0.16
      },
      "kind": "title",
      "text": "Advancing key programs in infectious diseases and oncology with high unmet need",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "156530b1-dbf6-4ec6-84e9-d5886b3b15a7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.96,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "title",
      "text": "Anticipated Near, Medium, and Long-Term Catalysts with the Potential to Drive Significant Shareholder Value",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ff9060ac-6f50-43a5-9d72-49d78ee75e7b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "590f4744-1e3f-4a00-aca8-9d6991529da6",
      "evidence": "Categorization of milestones into Near, Medium, and Long-Term buckets.",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 7,
      "from": 6,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "d0708d2e-7de6-42a6-ab2d-ed6b9fd3f9f5",
      "evidence": "The document presents the company's anticipated near, medium, and long-term catalysts and their potential to drive significant shareholder value.",
      "position": 1,
      "objective": "Why now is the right time to invest in AN2 Therapeutics?",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 0.6,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}